NCT Number,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures;;;;;;;;;;;;
"NCT04440449,""Frailty Scale Using Fried's Phenotype Method Based on Five Frailty Characteristics, 1. Self-reported (SR) exhaustion (Y/N ) on Center for Epidemiologic Studies Depression (CES-D) scale: """"Do you feel full of energy?"""" """"No"""" scored a 1 (exhausted).";;;;;;;;;;;;
"2. SR unintentional weight loss: """"In the last year, have you lost more than 10 pounds unintentionally?"""". """"Yes"""" scored a 1.";;;;;;;;;;;;
3. SR physical activity over the last year using the Minnesota Leisure Time Activity Questionnaire, (energy expenditure in kcal/week, standardized for sex). The lowest quintile for each sex group received a score of 1;;;;;;;;;;;;
4. Grip strength measured (Kg) with a dynamometer in the dominant hand, standardized using body mass index quartiles and sex. The average of 3 trials was recorded. The lowest quintile for each sex group received a score of 1 (for weak).;;;;;;;;;;;;
"5. 10 feet walked at usual pace, standardized based on height and sex. The fastest of 2 trials was recorded. Participants in the lowest quintile for each sex group were considered slow (score =1) A higher scale score from 0-5 indicates greater frailty, Baseline to 6 months"",""Glycated Hemoglobin (HbA1c), Change in HbA1c measured over the study period, Baseline to 6 months|Short Physical Performance Battery (SPPB) Balance, The balance test assesses a person's ability to stand with the feet together in side-by-side, semi-tandem, and full-tandem positions for 10 seconds each, responses ranging between 0-4 with a higher score indicating better balance. Three balance tests are performed and scoring is as follows:";;;;;;;;;;;;
;;;;;;;;;;;;
Side-by-side stand: person attempts to stand with feet together, side-by-side, for 10 seconds.;;;;;;;;;;;;
;;;;;;;;;;;;
* 1 point if held for 10 seconds;;;;;;;;;;;;
* 0 points if not held for 10 seconds or not attempted Semi-tandem stand: person attempts to stand with the side of the heel of one foot touching the big toe of the other foot for 10 seconds.;;;;;;;;;;;;
* 1 point if held for 10 seconds;;;;;;;;;;;;
* 0 points if not held for 10 seconds or not attempted Tandem stand: person attempts to stand with the heel of one foot in front of and touching the toes of the other foot for about 10 seconds.;;;;;;;;;;;;
* 2 points if held for 10 seconds;;;;;;;;;;;;
* 1 point if held for 3 to 9.99 seconds;;;;;;;;;;;;
* 0 points if held for \<3 seconds or not attempted, Baseline to 6 months|SPPB Gait Speed, Gait speed at a 4-meter walk is timed in seconds as participants walk at their usual pace. Two trials were administered, time (in seconds) was recorded for each trial. The fastest walk of two trials was recorded. Score is recorded between 0-4 with a higher score indicating a faster gait speed. Scoring is as follows:;;;;;;;;;;;;
;;;;;;;;;;;;
* 0 points if unable to do the walk;;;;;;;;;;;;
* 1 point if time is more than 8.70 sec;;;;;;;;;;;;
* 2 points if time is 6.21 to 8.70 sec;;;;;;;;;;;;
* 3 points if time is 4.82 to 6.20 sec;;;;;;;;;;;;
* 4 points if time is less than 4.82 sec, Baseline to 6 months|SPPB Chair Stands, Chair stand represents the time to complete five chair rises, sit to stand from a chair, as quickly as possible, without using hands, responses ranging between 0-4. Scoring is as follows:;;;;;;;;;;;;
;;;;;;;;;;;;
* 0 points if unable to complete 5 chair stands or completes stands in \>60 seconds;;;;;;;;;;;;
* 1 point if chair stand time is 16.70 sec or more;;;;;;;;;;;;
* 2 points if chair stand time is 13.70 to 16.69 sec or more;;;;;;;;;;;;
* 3 points if chair stand time is 11.20 to 13.69 sec;;;;;;;;;;;;
"* 4 points if chair stand time is 11.19 sec or less, Baseline to 6 months"",";;;;;;;;;;;;
"NCT02079805,""Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12), Change from the start of the treatment period (baseline) at the end of the treatment period (Week 12) was reported. Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405)., Baseline and Week 12"",""Change in Fasting Blood Glucose From Baseline at the End of the Treatment Period (Week 12), Change from baseline in fasting blood glucose values collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Change in Fasting Insulin From Baseline at the End of the Treatment Period (Week 12), Change from baseline in fasting insulin values collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Change in Glycosylated Hemoglobin (HbA1c) From Baseline at the End of the Treatment Period (Week 12), Change from baseline in the values of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-β) From Baseline at the End of the Treatment Period (Week 12), Change from baseline in HOMA-β collected at week 12 or final visit relative to baseline was reported. Homeostasis model assessment of beta cell function measures as following";" HOMA-β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}., Baseline and Week 12|Change in 1,5-anhydroglucitol (1,5-AG) From Baseline at the End of the Treatment Period (Week 12), Change from baseline in 1,5-G concentration collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Number of Participants With Treatment-Emergent Adverse Events, Up to Week 12"",";;;;;;;;;;;
"NCT02387749,""Measurement of b-FGF, v-EGF MEASURED BY ELISA, measurement of b-FGF and v-EGF MEASURED BY ELISA before (at zero), and after at (7 days, 90) days after stem cell transfusion to measure the effect of stem cell and its role in nerve regeneration, zero ( before) , 7 DAYS, 90 days|Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study., Measuring nerve conduction velocities(NCV) in m/sec upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line(zero day) and 90 days after stem cells transfusion, base line(zero dya), 90 days after stem cells transfusion.|Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study, Measuring nerve conduction latency in msec of upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line and 90 days after stem cells transfusion, base line(zero dya), 90 days after stem cells transfusion .|Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study., Measuring nerve conduction amplitudes in uv of upper and lower limbs nerves(sensory and motor).";;;;;;;;;;;;
;;;;;;;;;;;;
lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory .;;;;;;;;;;;;
;;;;;;;;;;;;
"upper limb nerves: ulnar nerve as motor and sensory. and compare at base line and 90 days after stem cells transfusion, base line(zero dya), 90 days after stem cells transfusion"",""Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion, fasting, 2 hours postprandial blood sugar measurement before at base line (zero day) and after (90 days) stem cells transfusion as a follow up and comparing the values., base line (zero day) and 90 days after stem cells transfusion|Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %, Blood tests before and after stem cells(90 days) transfusion and comparing the values in percent % which is reflecting the patient blood sugar control in the previous 3 months, at base line (zero day) and 90 days after stem cells transfusion"",";;;;;;;;;;;;
"NCT01512849,""Effect of Renal Function on Maximum Plasma Concentration of TA-7284, For 72 hours after each administration|Effect of Renal Function on Area Under the Plasma Concentration-time Curve From Zero up to Infinity of TA-7284, For 72 hours after each administration|Effect of Renal Function on Urinary Glucose Excretion of TA-7284, For 24 hours after each administration|Effect of Renal Function on Percent Inhibition of Renal Glucose Reabsorption (RGR) of TA-7284, The percent inhibition of renal glucose reabsorption was calculated from renal glucose reabsorption (eGFR × plasma glucose AUC - urinary glucose excretion) on the preceding day and on the day of administration., For 24 hours after each administration"",""Adverse Events, Incidence and severity of AEs, Upto approximately 14 days after last administration|12-lead Electrocardiogram (ECG), Change from baseline in ECG parameters, For 72 hours after each administration|Vital Signs, Change from baseline in Vital signs (BP, PR and BT), For 72 hours after each administration|Clinical Laboratory Tests, Change from baseline in Clinical laboratory tests, For 72 hours after each administration"",";;;;;;;;;;;;
"NCT00598663,""HbA1c at 6 Month, The end of period difference in HbA1c after 6 months of treatment, 6 months"",""Glycemic Variability, 24 h SD of glucose values (mg/dl), 6 months|Number of Severe Hypoglycemia Events, 6 months|Daily Min Spent in Euglycaemia (3.9-10.0 mmol/l), 6 months|Postprandial Glycaemia, Breakfast Postprandial glycaemia, 6 months|Pediatric Quality of Life Inventory (Vers 4.0"; PedsQL), This questionnaire is a validated assessment of health-related quality of life in children developed by J.W. Varni, (1998).;;;;;;;;;;;
;;;;;;;;;;;;
"Scores are transformed on a scale from 0 to 100. higher values represent a better outcome, 6 months|Diabetic Ketoacidosis Events, A diabetic ketoacidosis event (DKE) is defined as a hyperglycemia (blood glucose \>250 mg/dL) with either low serum bicarbonate (\<15 mEq/L) and/or low pH (\<7.3) and either ketonemia or ketonuria and requiring treatment within a health-care facility., 6 months"",";;;;;;;;;;;;
"NCT02280863,""Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL, no More Than Two Episodes With Meter Glucose Values Remaining >300 mg/dL for More Than 1 Hour, and no Ketonemia, Seizures, or Loss of Consciousness, Our definition of a subject successfully participating in a cohort is:";;;;;;;;;;;;
;;;;;;;;;;;;
1. No more than one meter glucose value \<50 mg/dL and no values \<40 mg/dL;;;;;;;;;;;;
2. No more than two episodes with meter glucose values remaining \>300 mg/dL for more than 1 hour that are unrelated to an infusion set failure;;;;;;;;;;;;
3. No ketonemia \>1.0 mmol/L, while the system is functional unless related to an intercurrent illness or infusion set failure;;;;;;;;;;;;
"4. No seizures or loss of consciousness while system is on and functional, Up to 10 days"",""Mean Glucose Values, Mean glucose values are reported as assessed by continuous glucose monitoring (CGM";" subcutaneous sensor, day and night values)., Up to 10 days|Mean Glucose Values, Fingerstick Glucose Meter Value, Adult Cohorts, Mean glucose values are reported as assessed by fingerstick glucose meter value., Up to 10 days|Median Glucose Values, Fingerstick Glucose Meter Value, Adolescent Cohort, Median an glucose values are reported as assessed by fingerstick glucose meter value., Up to 10 days|Percentage of Time Within Glucose Range of 70-180 mg/dL, Up to 10 days|Percentage of Fingerstick Meter Glucose Value Tests <70 mg/dL, Up to 10 days|Percentage of Time With Sensor Glucose Values <70 mg/DL, Adult Cohorts, Up to 10 days|Percentage of Time With Sensor Glucose Values <70 mg/DL, Adolescent Cohort, Up to 10 days|Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Medtronic Android Interface, Up to 10 days|Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Integrated System Interface and Adolescent Cohort, Up to 10 days"",";;;;;;;;;;;
"NCT03238963,""Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period, Percentage of participants with any ocular adverse events over the on-treatment period was reported., On-treatment period: from first dose of study drug until end of follow-up period, up to 24 weeks."",""Percentage of Participants With at Least 2 Steps Improvement From Baseline in the Study Eye on the Diabetic Retinopathy Severity Scale (DRSS) at Week 12, 7-field or modified 4-field digital fundus photographs was obtained from both eyes by a qualified person according to the imaging manual to collect all data for the assessment of the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS). The images was sent to the independent central reading center who performs the grading on the basis of the DRSS. The DRSS ranges from level 10 (Diabetic retinopathy absent) to level 85 (advanced proliferative Diabetic retinopathy)., At baseline and at Week 12.|Percentage of Participants With Adverse Events Other Than Ocular Adverse Events Over On-treatment Period, Percentage of participants with adverse events other than ocular adverse events over on-treatment period was reported., On-treatment period: from first dose of study drug until end of follow-up period, up to 24 weeks."",";;;;;;;;;;;;
"NCT02969863,""Percentage of Time Spent With Dexcom CGMG < 60 mg/dl, A measure of hypoglycemia capturing amount of time the continuous glucose monitor is reading less than 60 mg/dl, days 2-7"",,";;;;;;;;;;;;
"NCT01854593,""Reoperation, Vitreoretinal reoperation due to recurrent vitreous hemorrhage., 1 month"",""Intra Operative Hemorrhage, Calculate the number of coagulators for the intra operative hemorrhage., End of the surgery.|Postoperative Vitreous Hemorrhage., Postoperative vitreous hemorrhage that is permitted within 4 weeks after surgery., 1 month|Vascular Endothelial Growth Factor Concentration in Vitreous, Vascular endothelial growth factor concentration in vitreous at the start of vitrectomy., Start of surgery.|Endolaser Photocoagulation, Number of intraoperative endolaser photocoagulation., End of surgery.|Iatrogenic Retinal Tears, The number of participants who had intraoperative iatrogenic retinal tears., End of surgery.|Surgical Time, End of surgery.|Postoperative Best Corrected Visual Acuity, Best corrected visual acuity was measured using the Landolt ring chart, and the result was converted to logMAR notation for analysis.";;;;;;;;;;;;
;;;;;;;;;;;;
The minimum of the scale is 2.0 and the maximum of the scale is -0.3. The higher values represent a worse outcome., 1 mouth after surgery.|Best Corrected Visual Acuity Change, Best corrected visual acuity change was calculated by postoperative logMAR visual acuity minus preoperative logMAR visual acuity.;;;;;;;;;;;;
;;;;;;;;;;;;
"The higher values represent a worse outcome., 1 month|Postoperative Neovascular Glaucoma, The number of participants with progressive or persistent neovascular glaucoma after surgery., Within 1 month after the surgery.|Elevated Intraocular Pressure, The number of participants with elevated intraocular pressure after surgery., Within 1 month after the surgery.|Gas Tamponade, The number of participants with gas tamponade at the end of the surgery., End of surgery.|Silicon Oil Tamponade, The number of participants with silicon oil tamponade at the end of the surgery., End of surgery."",";;;;;;;;;;;;
"NCT02725593,""Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24, Baseline to Week 24"",""Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Baseline to Week 24|Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control, Baseline to Week 24|Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24, Baseline to Week 24"",";;;;;;;;;;;;
"NCT05130593,""Palatability of Bar, Participants were asked to rate the bar on a visual analog scale to indicate their impression of its visual appearance, smell, taste, texture, aftertaste, and overall pleasantness. The scale range for each attribute is 0-100 with higher scores equating to a better outcome., Test Day (immediately after taste-testing the bar)"",""Levels of Plasma BIoactive (DMC-2) Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb., Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of DMC-2. Nutrasorb bar: 250 kcal bar containing 30 g of PMI-5011/Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings, 10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption|Levels of Serum Glucose Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb., Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of safety parameters (glucose). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings, 10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption|Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb., Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of safety parameters (insulin). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings, 10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption"",";;;;;;;;;;;;
"NCT01217463,""Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Topical Daily Application of Trafermin 0.01% Spray Compared With Placebo, in Addition, Wound closure is defined as 100% reepithelialization of the target DFU, without exudate., 12 weeks"",""Relative Wound Area Regression of 40% or More at 6 Week, The incidence of wound area regression of at least 40% at week 6 was considered as an important exploratory secondary efficacy variable. The wound area regression was calculated as percentage change from inclusion at week 6 using centralized wound area data., 6 weeks"",";;;;;;;;;;;;
"NCT01272193,""Change in Glycosylated Haemoglobin (HbA1c), Observed change from baseline in HbA1c after 26 weeks of treatment, Week 0, Week 26"",""Mean Increment of 9-point Self Measured Plasma Glucose Profile (SMPG) at the Main Evening Meal, Observed mean increment of the 9-point self-measured plasma glucose profile (SMPG) at the main evening meal, Week 26|Rate of Treatment Emergent Adverse Events (AEs), Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect., Week 0 to Week 26 + 7 days follow up|Rate of Confirmed Hypoglycaemic Episodes, Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L., Week 0 to Week 26 + 7 days follow up|Rate of Nocturnal Confirmed Hypoglycaemic Episodes, Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m., Week 0 to Week 26 + 7 days follow up|Change in Body Weight, Observed change from baseline in body weight after 26 weeks of treatment, Week 0, Week 26"",";;;;;;;;;;;;
"NCT01230749,""Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG), Difference is calculated as the change in 24-hour WAG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. 24-hour WAG is defined as the area under the plasma glucose concentration time curve over 0 to 24 hours, divided by 24., From baseline (Day -1) to Day 28"",""Change From Baseline to Day 28 in Fasting Plasma Glucose (FPG), Difference is calculated as the change in FPG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change., From baseline to Day 28|Change From Baseline to Day 28 in Insulin Secretion, Difference is calculated as the change in insulin secretion in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insulin secretion is measured by the absolute change in Homeostasis Model Assessment of steady state islet beta cell (HOMA-%B). HOMA-%B calculated as: (360 multiplied by Insulin \[pmol/L\]) divided by (\[Glucose {mg/dL} minus 63\] multiplied by 6.945). Higher value is better (signifies improvement relative to baseline)., From baseline to Day 28|Change From Baseline to Day 28 in Insulin Resistance, Difference is calculated as the change in insulin resistance in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insuline sensitivity is measured by absolute change in Homeostasis Model Assessment of insulin resistance (HOMA-IR). Insulin sensitivity is HOMA-%S and HOMA-IR is the reciprocal of HOMA-%S. HOMA-IR calculated as: (Glucose \[mg/dL\]) multiplied by Insulin \[pmol/L\]) divided by (405 multiplied by 6.945). Lower value is better (signifies improvement relative to baseline)., From baseline to Day 28|Change From Baseline to Day 28 in Systemic Levels of Interleukin 6 (IL-6), Difference is calculated as the geometric mean change in IL-6 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-6 is a systemic inflammatory markers and is an independent predictors of insulin resistance and progression to type 2 diabetes mellitus. IL-6 was not measured for pioglitazone guoup. The unit of IL-6 is picograms per milliliter (pg/mL)., From baseline to Day 28|Change From Baseline to Day 28 in Systemic Levels of Interleukin 18 (IL-18), Difference is calculated as the geometric mean change in IL-18 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-18 was not measured for pioglitazone group. The unit of IL-18 is picograms per milliliter (pg/mL), From baseline to Day 28|Change From Baseline to Day 28 in Systemic Levels of C-Reactive Protein (CRP), Difference is calculated as the geometric mean change in CRP from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. CRP was not measured for pioglitazone group., From baseline to Day 28|Change From Baseline to Day 29 in Body Weight, Difference is calculated as the change in body weight in Least Square Mean (LSM) from baseline to Day 29 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change., From baseline to Day 29"",";;;;;;;;;;;;
"NCT01915849,""Area Under the Postprandial Curve (AUC) for Rate of Appearance (Ra) of Exogenous Glucose, Glucose fluxes during a mixed meal were measured using a dual glucose tracer method and non-steady state Steele equations. The rate of appearance of meal (or exogenous) glucose in the blood (also referred to as intestinal glucose absorption or Ra meal) after a mixed meal following LIK066 administration on Days 1 and 4 was the primary PD assessment in this study.The postprandial AUC was calculated using the linear trapezoidal rule. The sample collected at 7 hours after the start of the infusion was treated as the pre-meal, 0 hour measurement for the AUC0-5 hr calculation., Day 1 and Day 4 (pre-meal, every half hour till 5 hour on Day 1 and Day 4)"",,";;;;;;;;;;;;
"NCT02916563,""Number of Successful Glucose Readings, The success criterion for the performance of the Blood Glucose Monitoring System at high altitude (approximately 10,000 feet above sea level) means that 95% of the blood glucose readings fall within 15mg/dL of the YSI reference value (for reference values less than 75 mg/dL) and within 20% (for reference values greater than or equal to 75 mg/dL)., One day"",,";;;;;;;;;;;;
"NCT00480493,""Maternal Confidence Scale, Maternal confidence in managing child with type 1 diabetes . Higher total scores (10 questions, minimum score of 0, maximum score of 50) mean a better outcome (greater maternal confidence), 12 months|Parent Concern, Parent concern in managing child with type 1 diabetes. Higher total scores (58 questions, minimum score is 58";" maximum score is 255) means more worry with managing child's diabetes care., 12 months|Worry, Parent worry in managing child's care. Higher total scores (11 questions, minimum score is 11, maximum score is 44) indicate more parental worry, 12 months"",,";;;;;;;;;;;
"NCT00467649,""The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia, A severe hypoglycemia is defined as an event during which the patient required the assistance of another individual (including aid in ingestion of oral carbohydrate)";" and/or required the administration of glucagon injection, intravenous glucose, or other medical intervention., 24 Weeks"",""Percentage of Patients Achieving HbA1c <=7% at Week 24, This is a component of the primary endpoint, 24 Weeks|Percentage of Patients With no Weight Gain at Week 24, This is a component of the primary endpoint, 24 Weeks|Percentage of Patients With a Severe Hypoglycemia Adverse Event, This is a component of the primary endpoint., 24 Weeks|Change in HbA1c From Baseline at Week 24, Baseline values are presented in the Baseline Characteristics section, From Baseline to Week 24|Change in Body Weight From Baseline at Week 24, Baseline values are presented in the Baseline Characteristics section, From Baseline to Week 24|Change in Waist Circumference From Baseline at Week 24, Baseline values are presented in the Baseline Characteristics section, From Baseline to Week 24|Change in Fasting Plasma Glucose From Baseline at Week 24, Baseline values are presented in the Baseline Characteristics section, From Baseline to Week 24|Fasting Serum Lipids Change From Baseline to Week 24, Baseline, week 24|Phase 2: Change in HbA1c at Week 36, Two changes are calculated, the first by subtracting Week 36 value from the Phase 1 Baseline value (total change over 36 weeks), the second by subtracting the Week 36 value from the Phase 2 Baseline value (change from week 24 to week 36 only)., Phase 1 Baseline, Phase 2 Baseline at Week 24, Week 36|Phase 2: Change in Body Weight at Week 36, Two changes are calculated, the first by subtracting Week 36 value from the Phase 1 Baseline value (total change over 36 weeks), the second by subtracting the Week 36 value from the Phase 2 Baseline value (change from week 24 to week 36 only)., Phase 1 Baseline, Phase 2 Baseline at Week 24, Week 36"",""Hypoglycemia Adverse Events, MILD: patient reported symptoms consistent with hypoglycemia that may or may not have been documented by glucose monitoring at the time of symptoms. Symptoms did not greatly interrupt or interfere with the patients daily activities. Symptoms dissipated spontaneously or upon eating.";;;;;;;;;;;
;;;;;;;;;;;;
MODERATE: Patient reported symptoms consistent with hypoglycemia that may or may not have been documented by glucose monitoring at the time of symptoms. Symptoms interrupted or interfered with the patients daily activities and required immediate self treatment (e.g. carbohydrate ingestion).;;;;;;;;;;;;
;;;;;;;;;;;;
"SEVERE: Patient required the assistance of another individual (including aid in ingestion of oral carbohydrate): and/or required the administration of glucagon injection, intravenous glucose, or other medical intervention., 36 weeks""";;;;;;;;;;;;
"NCT01234649,""Insulin Secretion-Sensitivity Index (IS-SI), IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET), 84 weeks of treatment"",""Fasting Blood Glucose (FBG), Fasting glucose levels in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Mean Glucose During OGTT (MBG), MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Matsuda Insulin Sensitivity Index Derived From OGTT, OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Insulinogenic Index (IGI) /HOMA-IR, IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Absolute Body Weight, Body weight in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline), Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent., Change from baseline (time 0) to study end (84 weeks)|Body Mass Index (BMI), BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Waist Circumference (WC), Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET, 84 weeks of treatment|Waist-to-Hip Ratio (WHR), Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Waist to Height Ratio (WHtR), Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Total Cholesterol (CHOL) Levels, CHOL levels in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|High Density Lipoprotein Cholesterol (HDL-C) Levels, HDL-C levels in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Low Density Lipoprotein Cholesterol (LDL-C) Levels, LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Triglyceride (TRG) Levels, TRG concentrations in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C), TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Systolic Blood Pressure, SBP in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Diastolic Blood Pressure, DBP in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Alanine Aminotransferase (ALT) Levels, Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Aspartate Aminotransferase (AST), The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group, 84 weeks of treatment|Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio, ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group, 84 weeks of treatment"",";;;;;;;;;;;;
"NCT03687827,""Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM), The percentage of time spent in glycaemic target range was calculated as the number of recorded measurements in glycaemic target range (70-180 milligrams per deciliter \[mg/dL\] (3.9-10.0 millimoles per litre \[mmol/L\]), both inclusive) divided by the total number of recorded measurements. The endpoint is based on data recorded by FGM system. It was required that at least 70% of the planned FGM measurements during weeks 16-17 and weeks 34-35 were available for endpoint data to be included in the analysis., During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2)"",""Time Spent in Tight Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, Using Flash Glucose Monitoring, The percentage of time spent in tight glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, during the 2-week maintenance periods using FGM (visit 9-21 (week 16-17) and visit 37-39 (week 34-35))., During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).|Time Spent in Nocturnal Glycaemic Target Range 70-140 mg/dL (3.9-7.8 mmol/L) Both Inclusive, in the Nocturnal Period (00:01 am - 05:59 am Both Inclusive) Using Flash Glucose Monitoring, Percentage of time spent in nocturnal glycaemic target range 70-140 mg/dL (3.9-7.8 mmol/L) both inclusive, in the nocturnal period (00:01 am - 05:59 am both inclusive) during the 2-week maintenance periods using FGM (visit 19-21 (week 16-17) and visit 37-39 (week 34-35))., During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).|Level of Glycated Haemoglobin (HbA1c) - Percentage, Level of HbA1c after two weeks of maintenance periods (Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35))., After the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).|Level of Glycated Haemoglobin (HbA1c) - mmol/Mol, Level of HbA1c after two weeks of maintenance periods (Visit 19-21 (week 16-17) and Visit 37-39 (week 34-35))., After the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2).|Mean Glucose Levels Using Flash Glucose Monitoring (FGM), Mean glucose levels (mmol/L) during the 2-week maintenance periods using FGM (visit 19-21 (week 16-17) and visit 37-39 (week 34-35))., During the 2-week maintenance period: weeks 16-17 (period-1) and weeks 34-35 (period-2)."",";;;;;;;;;;;;
"NCT01413204,""Change in Hemoglobin A1c (A1C) From Baseline (NGSP Value), baseline and 24 weeks"",""Change in Fasting Plasma Glucose, Week 24|Change in Body Weight, Week 24|Change in Blood Pressure, Week 24|Change in Postprandial Plasma Glucose, Insulin and Urinary Glucose Excretion After a 75 g Oral Glucose Tolerance Test, Week 24|Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events, Laboratory Tests, 12-lead ECG and Vital Signs, Week 24"",";;;;;;;;;;;;
"NCT02048904,""Change in Microalbuminuria Level, Decrease in microalbuminuria level, Six months"",,";;;;;;;;;;;;
"NCT01462227,""Glucose (mg/dL), Glucose was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study., End of study (up to 240 minutes)|Glucose Infusion Rate (mg/kg.Min), The glucose infusion rate corresponds to the amount of 20% dextrose given during the hyperinsulinemic-hypoglycemic clamp study, necessary to keep blood glucose levels at the target range (50-55 mg/dL)., End of study (up to 240 minutes)"",""Glucagon (pg/mL), Glucagon was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study., End of study (up to 240 minutes)|Cortisol (ug/dL), Cortisol was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study., End of study (up to 240 minutes)|Epinephrine (pg/mL), Epinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study., End of study (up to 240 minutes)|Norepinephrine (pg/mL), Norepinephrine was measured in the blood throughout the hyperinsulinemic-hypoglycemic clamp study., End of study (up to 240 minutes)"",";;;;;;;;;;;;
"NCT03345004,""Change in Stimulated C-peptide During a MMTT, Change in C-peptide between Baseline and 15 Months. C-peptide was measured by Area Under the Curve \[AUC\] at 0-120 min during a Mixed Meal Tolerance Test (MMTT) and divided by 120 min. The results are given as the ratio (back-transformed from log-scale) between 15 Months and Baseline as predicted by the MMRM (Mixed Model Repeated Measures) model., Baseline and 15 months"",""Change in IDAA1c, Change in insulin-dose-adjusted HbA1c (IDAA1c), Baseline and 15 months|Change in HbA1c, Change in HbA1c (mmol/mol), Baseline and 15 months|Change in Insulin Consumption, Change in daily exogenous insulin consumption (IU), Baseline and 15 months|Change in Glycemic Variability/Fluctuations, Change in glycemic variability/fluctuations (evaluated from data from continuous glucose monitoring FreeStyle LibrePro, FGM) over 14 day period., Screening and 15 months|Percentage of Patients With IDAA1c ≤ 9, Percentage of patients with IDAA1c ≤ 9, 15 months|Stimulated Maximum C-peptide Above 0.2 Nmol/L, Percentage of patients with a stimulated maximum C-peptide level above 0.2 nmol/L (0.6 ng/ml), 15 months|Stimulated C-peptide Above 0.2 Nmol/L at 90 Min, Percentage of patients with a stimulated 90min C-peptide level above 0.2 nmol/L (0.6 ng/ml), 15 months|Number of Hypoglycemias, Number of self-reported episodes of severe hypoglycemia (Severe hypoglycemia defined as needing help from others and/or seizures and/or unconscious) (counts), Baseline and 15 months|Number of Patients Having at Least 1 Severe Hypoglycemic Event, Number of patients having at least 1 severe hypoglycemic event (counts), Baseline and 15 months|Change in Maximum C-peptide, Change in maximum C-peptide during MMTT (nmol/L), Baseline and 15 months|Change in Fasting C-peptide, Change in Fasting C-peptide (nmol/L), Baseline and 15 months|C-peptide Levels During a MMTT, C-peptide measured at 30, 60, 90, and 120 minutes during MMTT (nmol/L) at 15 months, 15 months|Change in Body Weight, Change in body weight (kg), Baseline and 15 months|Injection Site Reactions, Injection site reactions, 15 months|Number of Clinically Significant Abnormal Results From Laboratory Measurements (Haematology and Clinical Chemistry) and Urinalysis., Number of clinically significant abnormal results from laboratory measurements (haematology and clinical chemistry) and urinalysis. (counts), 15 months|Number of Clinically Significant Abnormal Results From Physical and Neurological Examinations, Physical examination (general appearance including skin, mouth, throat, cardiovascular, abdomen, lymphatic glands, and neurological/musculoskeletal \[including reflexes\]).";;;;;;;;;;;;
;;;;;;;;;;;;
Standardised clinical neurological examination including extremity reflexes, Romberg, Walk on a line, 2 meters, Standing on 1 leg, left and right, 15 seconds per leg, Finger-nose, Mimic, Babinski reflex.;;;;;;;;;;;;
;;;;;;;;;;;;
"The outcome of the assessments was recored as """"normal"""" or """"abnormal"""", 15 months|GAD65A Titer, GAD65A titer (IU/ml), Baseline and 15 months|Number of Clinically Significant Abnormal Results in Vital Signs, Vital signs (blood pressure) (mmHg), 15 months|Change in Quality of Life (QoL), Change in QoL as measured by the standardised measure of health questionnaire EQ-5D-5L between baseline and Month 15. The EQ-5D-5L is based on 5 questions rated at 5 levels indicating from no problem (level 1) to extreme problems (level 5) regarding current state of mobility, self-care, activity, pain and anxiety. The outcome is presented as a weighted index value, where 1 is the best possible health and 0 represents being dead., Baseline and 15 months|Change in Body Mass Index (BMI), Change in BMI (kg/m2), Baseline and 15 months"",";;;;;;;;;;;;
"NCT01196104,""Change in HbA1c (%) From Baseline to Week 16, Change from Baseline in glycated hemoglobin at Week 16, Baseline to Week 16"",""To Evaluate the Effect of Each Treatment on HbA1c, Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Comparison of Fasting Plasma Glucose (FPG) Levels at Randomization and Throughout the Study, Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Comparison of Post-prandial Glucose (PPG) Levels at Randomization and Throughout the Study, Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Glycomark and Fructosamine Levels Measured Throughout the Study, Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Seven-point Glucose at Randomization and Throughout the Study, Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Glycemic Excursions and Variability as Assessed Through Continuous Glucose Monitoring (CGM), Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Changes in Body Weight at 16 Weeks, Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Treatment Satisfaction as Assessed by Subject Treatment and Health Outcomes Questionnaires, Not analyzed due to early termination of the trial., Change from baseline to 16 weeks|Total Number of Cough Episodes, Total number of times patients coughed once, intermittently or continuously (inclusive), Baseline to Week 16|Severe Hypoglycemic Event Rate, Severe hypoglycemic event rate, ie, total number of events divided by subject-months of observation";;;;;;;;;;;;
;;;;;;;;;;;;
Severe hypoglycemia is defined as a subject who requires the assistance of another individual (not merely requested) and either:;;;;;;;;;;;;
;;;;;;;;;;;;
* SMBG levels ≤ 36 mg/dL OR;;;;;;;;;;;;
* There is a prompt response to the administration of carbohydrate, glucagon, or other resuscitative measures, Baseline to Week 16|Mild or Moderate Hypoglycemic Event Rate, Mild or moderate hypoglycemic event rate, ie, total number of events divided by subject-months of observation;;;;;;;;;;;;
;;;;;;;;;;;;
Nonsevere hypoglycemia is defined as a subject:;;;;;;;;;;;;
;;;;;;;;;;;;
* SMBG levels \< 70 mg/dL AND/OR;;;;;;;;;;;;
"* Symptoms that are relieved by the self-administration of carbohydrates, Baseline to Week 16|Number of Subjects Reporting Cough Episodes, Number of Subjects Reporting Cough Episodes, Baseline to Week 16|Number of Subjects Reporting Intermittent Coughing Episodes, Number of subjects reporting Intermittent Coughing Episodes, Baseline to Week 16|Number of Single Coughing Episodes, Total number of times patients coughed only once, Baseline to Week 16|Number of Cough Episodes Occuring Within 10 Minutes of Drug Inhalation, Baseline to Week 16|Baseline Forced Expiratory Volume in 1 Second (FEV1), Baseline FEV1, Baseline|Week 16 Forced Expiratory Volume in 1 Second, Week 16 FEV1, Week 16|Week 16 Change From Baseline in Forced Expiratory Volume in 1 Second, Week 16 Change from Baseline in FEV1, Baseline to Week 16|Week 20 (Follow-up) Forced Expiratory Volume in 1 Second, Week 20 (Follow-up) FEV1, 4 weeks after discontinuation of study treatment, Week 20 (Follow-up)|Week 20 (Follow-up) Change From Baseline in Forced Expiratory Volume in 1 Second, Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FEV1, Baseline to Week 20|Baseline Forced Vital Capacity (FVC), Baseline FVC, Baseline|Week 16 Forced Vital Capacity, Week 16 FVC, Week 16|Week 16 Change From Baseline Forced Vital Capacity, Week 16 Change from Baseline FVC, Baseline to Week 16|Week 20 (Follow-up) Forced Vital Capacity, Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) FVC, Week 20|Week 20 (Follow-up) Change From Baseline in Forced Vital Capacity, Week 20 (Follow-up, 4 weeks after discontinuation of study treatment) Change from Baseline in FVC, Baseline to Week 20"",";;;;;;;;;;;;
"NCT01710527,""Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose, Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified., Pre- dose (0.0 hour), post-dose at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0 and 36.0 hour in each period.|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) and Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-infinity), Plasma samples for PK analysis were drawn at indicated time points of each treatment period.";;;;;;;;;;;;
;;;;;;;;;;;;
"AUC0-t was calculated by the linear trapezoidal rule from measured data points from time of administration until the time of last quantifiable concentration. AUC0- infinity was estimated by linear trapezoidal rule and was sum of the AUC0-t and extrapolated to infinity by dividing the estimated last measurable plasma concentration by elimination rate constant. The AUC0- infinity was the sum of the estimated and extrapolated parts., Pre- dose (0.0 hour), post-dose at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0 and 36.0 hour in each period.|Time of the Maximum Plasma Concentration (T-max) Over Period, Plasma samples for PK analysis were drawn at indicated time points of each treatment period. If the maximum value occurs at more than one point T-max was defined as the first time point with this value., Pre- dose (0.0 hour), post-dose at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0 and 36.0 hour in each period.|Terminal Half-life (T-half) Over Period, Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The elimination or terminal half-life was calculated by dividing 0.693 (natural logarithm of 2) with elimination rate constant obtained as semi logarithmic plot of the plasma concentration versus time., Pre- dose (0.0 hour), post-dose at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0 and 36.0 hour in each period.|Percentage of Area Under Curve Extrapolated to Arrive at AUC0-infinity (AUC%_Extrapolated), Plasma samples for PK analysis were drawn at indicated time points of each treatment period. AUC%_Extrapolated was obtained by subtracting AUC0-t from AUC0-infinity divided by AUC0-infinity and multiplied by 100., Pre- dose (0.0 hour), post-dose at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0 and 36.0 hour in each period.|Apparent First-order Elimination or Terminal Rate Constant, Plasma samples for PK analysis were drawn at indicated time points of each treatment period. The apparent first-order elimination or terminal rate constant was calculated from a semi logarithmic plot of the plasma concentration versus time. The parameter was calculated by linear least-square regression analysis using the last three (or more) non-zero plasma concentrations., Pre- dose (0.0 hour), post-dose at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0 and 36.0 hour in each period."",""Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE), An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase \>=3 x upper limit of normal (ULN), and total bilirubin \>=2 x ULN or international normalized ratio \>1.5., Up to 38 days|Number of Participants With Abnormal Vital Sign Results, Vital signs measurements (blood pressure, respiratory rate, pulse rate and oral temperature) were conducted during screening and during post study safety assessments. Vital signs measurement were also performed at each check-in and at checkout and were also recorded before dosing of study drug, between 2-3, 9-10 and 36.0 hour post-dose. Measurements were recorded in sitting position after rest of at least 5 min., Up to 38 days|Number of Participants With Abnormal Periodic Physical Examination Results, Brief physical examination was performed at each check-in, check-out and complete physical examination during screening and at the end of the clinical part of the study., Up to 38 days|Assessment of Subject Well-being Questionnaire, Subject well-being questionnaire was planned to be conducted at 1.0 and 5.0 hour post-dose. During vital sign recording each participants was planned to be asked about his well-being recorded during post study safety assessments. The data for this outcome measure was not collected during the study. Thus the results summary for this outcome measure was not produced., Up to 38 days"",";;;;;;;;;;;;
"NCT00788827,""Number of Participants Who Experienced Adverse Events, Safety will be evaluated in terms of adverse events graded according to CTCTAE toxicity criteria and laboratory test results. All adverse events will also be graded for relationship to treatment and as expected and unexpected., 14 days"",""Hba1C Data of Pre and Post Stem Cell Infusion, Mean HbA1c laboratory measurements pre and post stem cell infusion, 12 weeks|Insulin Level, Mean insulin requirement was calculated for each participant pre and post stem cell infusion, 12 weeks|Amylase Level, Each participant had mean amylase data analysed to give a pre and post mean result, 12 weeks|Serum Creatinine, Each participant had serum creatinine analysis pre and post stem cell infusion to give mean result, 12 weeks"",";;;;;;;;;;;;
"NCT01809327,""Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26, The change in the value of glycated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) from baseline at Week 26 was compared between the different treatment groups., Day 1 (Baseline) and Week 26"",""Percent Change in Body Weight From Baseline to Week 26, The percentage change in body weight from baseline to Week 26 was compared between the different treatment groups., Day 1 (Baseline) and Week 26|Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26, The percentage of participants achieved HbAIc less than 7 percent at Week 26 was compared between the different treatment groups., Week 26|Change in Systolic Blood Pressure From Baseline at Week 26, The change in systolic blood pressure from baseline at Week 26 was compared between the different treatment groups., Day 1 (Baseline) and Week 26|Percent Change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26, The percentage change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) from baseline to Week 26 was compared between the different treatment groups., Day 1 (Baseline) and Week 26|Percent Change in Triglycerides From Baseline to Week 26, The percentage change in triglycerides from baseline to Week 26 was compared between the different treatment groups., Day 1 (Baseline) and Week 26|Number of Participants With Treatment Emergent Adverse Events (AEs), An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death"; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity;" congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state., Up to 30 weeks of last study drug administration"",";;;;;;;;
"NCT00592904,""Mean Change From Baseline in Short Form-McGill Pain Questionnaire (SF-MPQ): Sensory and Affective Scores, From Baseline to Week 48., Mean change from baseline to open-label study endpoint and other study visits in SF-MPQ scores sensory and affective). SF-MPQ was completed to assess intensity of pain over the past 48 days for all 15 descriptors: throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, splitting,tiring-exhausting, sickening, fear-causing, punishing-cruel. Each descriptor was scored by participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0-45)"; higher scores indicated higher intensity of pain., Baseline and Week 48|Mean Change From Baseline in SF-MPQ Visual Analog Scale (VAS): From Baseline to Week 48., SF-MPQ VAS consists of a line 0 to 100 millimeters (mm) in length;" range is 0 (no pain) to 100 mm (worst possible pain). Subjects placed a mark indicating the intensity of their pain. Distance from left-hand end of line was measured and entered on Case Report Form (CRF) as score in mm. Higher score indicates greater level of pain., Baseline and Week 48|Mean Change From Baseline in SF-MPQ Current Pain Intensity (CPI): From Baseline to Week 48, Mean change from baseline in SF-MPQ (CPI) at study endpoint. Affective score ranges from 0-5. Higher scores indicate more severe pain (0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible, 5=excrutiating)., Baseline and Week 48"",""Analysis of Patient Global Impression of Change (PGIC) at Week 48/End of Treatment (EOT), The PGIC asked subjects to evaluate the change in their overall status compared with the start of open-label treatment on a scale ranging from 1 (very much improved) to 7 (very much worse). \[Please note high withdrawl rate during study\]., Baseline and Week 48|Mean Change From Baseline in Short Form 36 Item (SF-36) Health Survey: Physical and Mental Component Scores From Baseline to Week 48/EOT, Mean change from baseline in SF-36 Item Health Survey Scores at study endpoint. Each component on the SF-36 Item Health Survey is scored from 0-100 with higher scores reflecting better subject status., Baseline and Week 48"",";;;;;;;;;;
"NCT00672204,""The Proportion of Insulin-independent Subjects With Full Islet Graft Function, Islet transplant recipients will be considered insulin-independent with full islet graft function if they are able to titrate off insulin therapy for at least 1 week and all of the following criteria are met:";;;;;;;;;;;;
;;;;;;;;;;;;
* HbA1c \< 7.0% or a ≥2.5% decrease from baseline;;;;;;;;;;;;
* fasting capillary glucose level should not exceed 140 mg/dL (7.8 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 7 times in a seven day period);;;;;;;;;;;;
* 2-hour post-prandial capillary glucose should not exceed 180 mg/dl (10.0 mmol/L) more than three times in the past week (based on measuring capillary glucose levels a minimum of 21 times in a seven day period);;;;;;;;;;;;
* fasting serum glucose level ≤126 mg/dL (7.0 mmol/L); if the fasting serum glucose level is \>126 mg/dL (7.0 mmol/L), it must be confirmed in an additional one out of two measurements;;;;;;;;;;;
"* evidence of endogenous insulin production defined as fasting or stimulated C-peptide levels ≥0.5 ng/mL (0.16 nmol/L)., 1 year following the first islet transplant"",,";;;;;;;;;;;;
"NCT01143727,""Wound Appearance, Weekly wound appearance as assessed by BWAT-m scores. BWAT-m scores used to determine primary efficacy consist of 8 subscales, each grade an aspect of wound status on a 1-5 scale"; 1=normal intact skin;" 5=least desirable. Total score=8-40. Subscales: Edges, Undermining, Necrotic Tissue Type, Necrotic Tissue Amount, Exudate Type, Exudate Amount, Skin Color Surrounding Wound, and Granulation Tissue., 28 days"",""Percent Change in Wound Area, 28 days"",";;;;;;;;;;
"NCT02660827,""Age 2-13 Years Old Subjects Change in A1C, Descriptive analysis of change in A1C from baseline to end of 3-month study period, Baseline and end of 3-month study period"",""Age 2-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL), mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months study period, baseline and 3 months|Age 2-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (> 180 mg/dL), mean change in % of time in hyperglycemia (\> 180 mg/dL) from baseline to 3 months study period, baseline and 3 months|Age 2-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (<70 mg/dL), mean change in % of time in hypoglycemia (\< 70 mg/dL) from baseline to 3 months study period, baseline and 3 months|Age 2-13 Years Old - Number of Severe Hypoglycemic Event, Number of severe hypoglycemic events occurred during 3-month study period., 3 months|Age 2-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event, Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month study period., 3 months|Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL, Event rate without Hypoglycemia at YSI-FST \<=65 mg/dL among 105 subjects who underwent the PLGM experiments. The event rate without hypoglycemia is the number of experiments without hypoglycemia/total number of experiments and hypoglycemic events are defined based on the occurrence of 2 or more continuous YSI-FST \<= 65mg/dL during in-clinic procedures., Up to 12 hours after the start of PLGM period"",";;;;;;;;;;;;
"NCT01183104,""Change From Baseline in HbA1c at 52 W, Baseline and 52 W|Number of Participants With Hypoglycaemia, From baseline to 52 W"",""The Number of Participants Achieving HbA1c < 6.9 %, 52 W|Change From Baseline in HOMA-β at 52 W, β cell function is measured by the Homeostatic Model Assessment(HOMA-β). HOMA β = \[20 x fasting insulin (μU/mL)\] / \[fasting plasma glucose (mmol/L) - 3.5\], Baseline and 52 W|Change From Baseline in Insulin/Proinsulin Ratio at 52 W, Baseline and 52 W|Change From Baseline in Body Weight at 52 W, Baseline and 52 W"",";;;;;;;;;;;;
"NCT00529204,""Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy, 24 weeks"",""Changes in Components of Liver Histology at Baseline and Week 24 Including Steatosis, Inflammation and Fibrosis, Steatosis was grades on a scale of 0 (\< 5%)"; 1 (5%- 33%); 2 (\> 33% - 66%); and 3 (\> 66%).;;;;;;;;;
;;;;;;;;;;;;
Inflammation was graded on a scale of 0 (No foci); 1 (\< 2 foci per 200 X field); 2 (2-4 foci per 200 X field); and 3 (\>4 foci per 200 X field) Fibrosis was graded on a scale of 0 (None); 1 (Mild periportal or perisinusoidal); 2 (Moderate periportal or perisinusoidal); 3 (Bridging fibrosis);" and 4 (cirrhosis), 24 weeks|Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes, 24 weeks"",";;;;;
"NCT03377127,""Hemoglobin A1c at 6 Months, change from baseline in Hemoglobin A1c, measured in % DCCT (Diabetes Control and Complications Trial) units, 6 months|Hemoglobin A1c at 12 Months, change from baseline in Hemoglobin A1c, 12 months"",""Hemoglobin A1c Less Than 8% at 6 Months, Percentage of patients achieving a hemoglobin A1c measurement of less than 8.0%, 6 months|Hemoglobin A1c Less Than 8% at 12 Months, Percentage of patients achieving a hemoglobin A1c measurement of less than 8.0% DCCT units, 12 months|Change in Hemoglobin A1c From 6 to 12 Months, The change in hemoglobin A1c (HbA1c), between 6 months and 12 months after randomization., 12 months|Achievement of Annual Lipid Panel Testing, percentage of patients complying with annual lipid testing, 12 months|Statin Compliance, Percentage of patients compliant with statin therapy per the 2013 American College of Cardiology / American Heart Association guidelines., 12 months|Blood Pressure, Percentage of patients achieving Blood pressure goal of less than 140/90 at the end of the trial period., 12 months|Annual Retinopathy Examination, Percentage of patients compliant with annual retinopathy examination, 12 months|Annual Nephropathy Examination, Percentage of patients compliant with annual nephropathy examination, 12 months|Annual Neuropathy Examination, Percentage of patients compliant with annual neuropathy examination, 12 months|Annual Influenza Vaccine, Percentage of patients compliant with annual influenza vaccine, 12 months|Annual Pneumonia Vaccine, Percentage of patients compliant with annual pneumonia vaccine, 12 months|Quality of Life Assessment, Difference between quality of life assessment via the World Health Organization BREF-Quality Of Life at baseline and 12 months.The WHOQOL-BREF consists of 4 domains, Physical Health, Psychological, Social Relationships, and Environment. Each domain is comprised of multiple questions that are considered together in the derivation of each domain score. In addition to the 4 domains, the WHOQOL-BREF includes two stand-alone questions to assess rated QOL and Satisfaction with Health questionnaire administered at baseline and at the conclusion of the trial period. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life) and range from a minimum of 4 to a maximum of 20. The mean score of items within each domain is used to calculate the domain score.A Likert scale from 1-7 was used. (1 - not affected, 7- extremely affected) We compared and reported the mean difference in between 6 months data and baseline data., 12 months|Diabetes Related EC Visits at 6 Months, Number of Emergency Center (EC) visits related to hyperglycemia or hypoglycemia, 6 months|Diabetes Related EC Visits at 12 Months, Number of Emergency Center (EC) visits related to hyperglycemia or hypoglycemia, 12 months|Total EC Visits at 6 Months, Number of Emergency Center (EC) visits, 6 months|Total EC Visits at 12 Months, Number of Emergency Center (EC) visits, 12 months|Inpatient Visits, Total number of inpatient visits, 12 months|Outpatient Visits, total number of outpatient visits, 12 months|No-show, percentage of visits missed in clinic, 12 months"",";;;;;;;;;;;;
"NCT01359904,""Hemoglobin A1c Levels, post intervention hemoglobin A1c levels, 3 months"",""Episodes of Hypoglycemia, record number of episodes during dialysis with serum glucose below 4 mmol/L by glucometer, 3 months|To Record the Effects of a Higher Dialysate Concentration of Glucose on Glycemic Control of Hemodialysis Patients With Type 2 Diabetes Mellitus by Measuring Serum Levels of Hemoglobin A1c., Hemoglobin A1c levels will be measured before the intervention and after to assess any difference in the value. The blood samples were taken prior to dialysis treatments mid-week for each subject at baseline and at the end of the study in both the control and intervention groups., 3 months|the Number of Infections Related to Vascular Access in Dialysis Among Those Who Receive a Higher Glucose Concentration in the Dialysate and Those Who Receive the Standard Concentration, In the two groups, we will measure the number of episodes of vascular access related infections ie. catheter, AV fistula or AV graft associated infections in the study period. The episode was defined as a diagnosis in the chart written by the nurse or physician with a prescription of antibiotics., 3 months"",";;;;;;;;;;;;
"NCT00123604,""Flow Mediated Dilation, Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion., change from baseline to 5 months"",,";;;;;;;;;;;;
"NCT04235504,""HbA1c 6 Months Change Between AHCL and MDI, The difference in the mean HbA1c change (6 months - baseline) between the AHCL and the MDI + FGM arm will be evaluated (Cohort A)., Baseline and end of 6-month study phase"",""TIR Between 70-180 mg/dL, % Time spent within range with sensor glucose (SG) between 70 - 180 mg/dL (3.9-10.0 mmol/L). The difference in the mean between the AHCL and the MDI + FGM arm will be evaluated (Cohort A)., 6 months study phase|Time in Hyperglycemic Range, % Time spent in hyperglycemic range with SG \> 180 mg/dL (\> 10.0 mmol/L). The difference in the mean between the AHCL and the MDI + FGM arm will be evaluated (Cohort A)., 6 months study phase|Hypoglycemic Events, Number of biochemical hypoglycemic events\< 54 mg/dL (3.0 mmol/L) (defined as sensor values \< 54 mg/dL (3.0 mmol/L) per 15 consecutive minutes (Danne, 2017). When the time between two successive events is less than 30 minutes, they will be combined and counted as one event. The difference in the mean between the AHCL and the MDI + FGM arm will be evaluated (Cohort A), 6 months study phase"",""HbA1c 6 Months Change Between AHCL and MDI, The difference in the mean HbA1c change (6 months - baseline) between the AHCL and the MDI + CGM arm will be evaluated (Cohort B)., Baseline and end of 6-month study phase|TIR Between 70-180 mg/dL, % Time spent within range with sensor glucose (SG) between 70 - 180 mg/dL (3.9-10.0 mmol/L). The difference in the mean between the AHCL and the MDI + CGM arm will be evaluated (Cohort B)., 6 months study phase|Time in Hyperglycemic Range, % Time spent in hyperglycemic range with SG \> 180 mg/dL (\> 10.0 mmol/L). The difference in the mean between the AHCL and the MDI + CGM arm will be evaluated (Cohort B)., 6 months study phase|Hypoglycemic Events, Number of biochemical hypoglycemic events\< 54 mg/dL (3.0 mmol/L) (defined as sensor values \< 54 mg/dL (3.0 mmol/L) per 15 consecutive minutes (Danne, 2017). When the time between two successive events is less than 30 minutes, they will be combined and counted as one event. The difference in the mean between the AHCL and the MDI + CGM arm will be evaluated (Cohort B)., 6 months study phase|HbA1c 6 Months Change Within Group, The change in the mean HbA1c from end of 6-month study phase to end of 6-month continuation phase will be evaluated (Cohort A), End of 6-month study phase and end of 6-month continuation phase|HbA1c 12 Months Change Between Groups, The difference in the mean HbA1c change (12 months - baseline) between treatment arm and control arm will be evaluated (Cohort A), Baseline through the end of 6-month continuation phase (a total of 12 months)|HbA1c 6 Months Change Within Group, The change in the mean HbA1c from end of 6-month study phase to end of 6-month continuation phase will be evaluated (Cohort B)., End of 6-month study phase and end of 6-month continuation phase|HbA1c 12 Months Change Between Groups, The difference in the mean HbA1c change (12 months - baseline) between treatment arm and control arm will be evaluated (Cohort B)., Baseline through the end of 6-month continuation phase (a total of 12 months).""";;;;;;;;;;;;
"NCT02648204,""Change in HbA1c, Results are based on HbA1c data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on-treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., Week 0, week 40"",""Change in Body Weight (kg), Results are based on body weight data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication., Week 0, week 40|Change in Fasting Plasma Glucose, Results are based on fasting plasma glucose data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication., Week 0, week 40|Change in Systolic and Diastolic Blood Pressure, Results are based on systolic and diastolic blood pressure data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication., Week 0, week 40|Change in Overall Scores for Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire, The questionnaire contains 8 items and evaluates subjects' diabetes treatment in terms of convenience, flexibility and general feelings towards treatment. The result presented is 'Treatment Satisfaction' summary score (sum of 6 of the 8 items). Response options: 6 (best case) to 0 (worst case). Total scores range: 0-36. Higher scores=higher satisfaction. Results are based on data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This includes observations recorded at, or after the date of first dose of trial product and not after first occurrence of following: the end-date of the 'on-treatment' observation period or initiation of rescue medication, Week 0, week 40|HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target, Percentage of subjects who achieved HbA1c target below or equal to 6.5% (48 mmol/mol) after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., After 40 weeks treatment|Change From Baseline in 7-point Self-measured Plasma Glucose (SMPG) Mean Profile, SMPG values were recorded at 7 time-points: before and 90 minutes after start of breakfast, lunch, and dinner, and at bedtime. Reported results are mean profile from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., Week 0, week 40|Change From Baseline 7-point Self-measured Plasma Glucose Increment, SMPG values were recorded at 7 time-points: before and 90 minutes after start of breakfast, lunch, and dinner, and at bedtime. Reported results are plasma glucose incremental profile from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes observations recorded at, or after date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit, Week 0, week 40|Change in Fasting Blood Lipids (Total Cholesterol), Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value., Week 0, week 40|Change in Fasting Blood Lipids (Low Density Lipoprotein [LDL] Cholesterol), Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value., Week 0, week 40|Change in Fasting Blood Lipids (High Density Lipoprotein [HDL] Cholesterol), Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value., Week 0, week 40|Change in Fasting Blood Lipids (Triglycerides), Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value., Week 0, week 40|Change in Body Mass Index (BMI), Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., Week 0, week 40|Change in Waist Circumference, Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., Week 0, week 40|Change in Short Form Health Survey (SF-36v2™), The questionnaire contains 36 items across 8 domains and 2 summary scores. Score range: 0 (worst score) to 100 (best score). Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., Week 0, week 40|Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c <7.0% (53 mmol/Mol) American Diabetes Association (ADA) Target, Percentage of subjects who achieved HbA1c target below or equal to \<7.0% (53 mmol/mol) after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., After 40 weeks of treatment|Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥5%, Percentage of subjects who achieved weight loss ≥5% after 40 weeks of treatment. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., After 40 weeks treatment|Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥10%, Percentage of subjects who achieved weight loss ≥10% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., After 40 weeks treatment|Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c <7.0% (53 mmol/Mol) Without Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain, Percentage of subjects achieved (yes/no) HbA1c \<7.0% (53 mmol/mol) without severe or BG confirmed symptomatic hypoglycaemia episodes and no weight gain after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was subset of 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit, After 40 weeks of treatment|Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c Reduction ≥1%, Percentage of subjects who achieved (yes/no) HbA1c reduction of ≥1% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., After 40 weeks of treatment|Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥3%, Percentage of subjects who achieved (yes/no) weight loss of ≥3% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., After 40 weeks treatment|Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c Reduction ≥1% and Weight Loss ≥3%, Percentage of subjects who achieved (yes/no) HbA1c reduction ≥1% and weight loss ≥3% 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., After 40 weeks treatment|Number of Treatment Emergent Adverse Events (TEAEs), A TEAE was defined as an AE with onset in the 'on-treatment' period (information collected while subjects were considered as exposed to trial product). This corresponded to information collected until the follow-up (5 weeks after the last treatment including a visit window of +7 days)., 40 weeks + follow-up of 5 weeks|Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemia Episodes, A treatment emergent hypoglycaemic episode was defined as an episode with onset in the 'on-treatment' period (information collected while subjects were considered as exposed to trial product). This corresponded to information collected until the follow-up (5 weeks after the last treatment including a visit window of +7 days). Severe or BG-confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the American Diabetes Association classification or BG-confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia., 40 weeks + follow-up of 5 weeks|Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes, Percentage of subjects with treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes. A treatment emergent hypoglycaemic episode was defined as an episode with onset in the 'on-treatment' period (information collected while subjects were considered as exposed to trial product). This corresponded to information collected until the follow-up (5 weeks after the last treatment including a visit window of +7 days). Severe or BG-confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the American Diabetes Association classification or BG-confirmed by a plasma glucose value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia., 40 weeks + follow-up of 5 weeks|Change in Amylase, Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value., Week 0, week 40|Change in Lipase, Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value., Week 0, week 40|Change in Pulse Rate, Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit., Week 0, week 40"",";;;;;;;;;;;;
"NCT02059005,""Change in Substance Use Rates From Baseline, Urinalysis confirmed self-reported days of use for any substance, including alcohol, cocaine, marijuana, opiates, sedatives, and hallucinogens over time. Participants reported substance use for the 90 days prior to the assessment date., 0, 3, 6 months"",""Change in Treatment Session Attendance From Baseline, Treatment sessions attended for alcohol or drug use issues over time. Participants self-reported attendance for the 6 months prior to the baseline assessment. During follow-up assessments, participants self-reported attendance since the last assessment date., 0, 3, 6, months|Number of Hospitalizations and Use of Emergency Services, Days of hospitalization and days of use of acute emergency services after Baseline. Participants self-reported their service utilization for the 6 months prior to the baseline assessment. During follow-up assessments, participants self-reported their service utilization since the last assessment date., 0, 3, 6, months"",";;;;;;;;;;;;
"NCT00091949,""Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction, Up to 5 years"",""Fatal or Non-fatal Stroke Alone, 5 years|Acute Coronary Syndrome, Fatal or non-fatal acute myocardial infarction or unstable angina, 5 years|Development of Overt Diabetes, 5 years|All Cause Mortality, 5 years|Decline in Cognitive Status, Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100., Annual measures from baseline to exit (up to 5 years)|Composite Outcome of Fatal or Non-fatal Stroke, Fatal or Non-fatal MI or Episode of Serious Congestive Heart Failure, 5 years"",";;;;;;;;;;;;
"NCT03188263,""Change in Glucose Levels (Area-under-the-curve) Measured by Performance on Oral Glucose Tolerance Test (OGTT), The OGTT is a 3-hour procedure measuring blood glucose levels after the patient has consumed a 75-gram dextrose solution at -15 min, 0 min, 30 min, 60 min, 90 min, 120 min, and 180 min intervals. Total area-under-the-curve of glucose levels is calculated., Change from baseline to after 4 weeks of light treatment"",""Changes in Circadian Phase Measured by Dim Light Melatonin Onset (DLMO), The DLMO is measured via saliva samples collected during laboratory sessions. A sample is collected every half hour until bedtime starting 6.5 hours before habitual bedtime, and conducted in dim light setting to identify the point when melatonin starts being released., Change from baseline to after 4 weeks of light treatment."",";;;;;;;;;;;;
"NCT01453049,""Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24, Blood samples of participants were collected for HbA1c assessment. HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3-month period. The American Diabetes Association has recommended an HbA1c value below 53 millimoles per mole (mmol/mol) (7.0%) for most participants. Change from Baseline in HbA1c was calculated as the value at Week 24 minus the value at Baseline., Baseline (Week 0) and Week 24"",""Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Blood samples of participants were collected for FPG assessment. The FPG test, also known as the fasting blood sugar test, measures blood sugar levels after the participant has not eaten (fasted) for 12 to 14 hours. Change from Baseline in FBG was calculated as the value at Week 24 minus the value at Baseline., Baseline (Week 0) and Week 24|Number of HbA1c Responders and Non-responders, Blood samples of participants were collected for HbA1c assessment. HbA1c responders were defined as participants who had achieved HbA1c \<7%, or who achieved a decrease of \>= 0.7% from Baseline at Week 24 (LOCF)., Baseline (Week 0) and Week 24 (LOCF)|Number of FPG Responders and Non-responders, Blood samples of participants were collected for FPG assessment. FPG responders are definded as participants who had a \>=1.7 mmol/L decrease from Baseline FPG or who achieved a FPG level \< 6.1 mmol/L at Week 24 (LOCF)., Baseline (Week 0) and Week 24 (LOCF)|Number of Participants Who Achieved HbA1c <7%, HbA1c <=6.5%, or Who Achieved a Decrease of >=0.7% From Baseline, Blood samples of participants were collected for HbA1c assessment., Baseline (Week 0) and Week 24 (LOCF)|Change From Baseline in Fasting Proinsulin and Insulin at Week 24/Early Withdrawal (EW), Blood samples of participants who had fasted for 12-14 hours were collected for fasting proinsulin (precursor of insulin) and insulin assessment. Preproinsulin is sequentially processed via proinsulin, through intermediate proteolytic cleavage products, to insulin and C-peptide before release from the beta cell granule by exocytosis. Elevated levels of proinsulin are considered indicative of beta cell dysfunction. Insulin is a hormone that regulates carbohydrate and fat metabolism in the body. Change from Baseline was calculated as the value at Week 24/ EW minus the value at Baseline (Week 0)., Baseline (Week 0) and Week 24/EW|Change From Baseline in Homeostasis Model Assessment Sensitivity (HOMA-S) at Week 24/EW, Blood samples of participants who had fasted for 12-14 hours were collected for fasting glucose (FG) and insulin (FI) assessment. The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance (a condition in which natural hormone insulin becomes less effective in lowering blood sugars) and beta-cell (specialized cells in the pancreas producing insulin) function. HOMA-S is calculated using the following model to predict glucose and insulin concentrations=(FI\[milliunits (mU)/milliliter (ml)\]\*FG \[millimoles per liter (mmol/l)\])/22.5. numerator, num."; denominator, denom., Baseline (Week 0) and Week 24/EW|Change From Baseline in Homeostasis Model Assessment Beta-cell Function (HOMA-B) at Week 24/EW, Blood samples of participants who had fasted for 12 to 14 hours were collected for fasting glucose (FG) and insulin (FI) assessment. The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance (a condition in which natural hormone insulin becomes less effective in lowering blood sugars) and beta-cell (specialized cells in the pancreas producing insulin) function. HOMA-B is calculated using the following mathematical model to predict glucose and insulin concentrations=(20\*FI\[mU/ml\])/(FG\[mmol/l\]-3.5)., Baseline (Week 0) and Week 24/EW|Number of Participants at Various Dose Levels at Week 24/EW, The number of participants at the different dose levels at Week 24/EW was recorded. The different dose levels for Rosi + Glim are: Dose level 1, Rosi 4 mg + Glim 1 mg; Dose level 2, Rosi 4 mg + Glim 2 mg; Dose level 3, Rosi 4 mg + Glim 4 mg. The different dose levels for Glim are: Dose level 1, Glim 1 mg; Dose level 2, Glim 2 mg; Dose level 3, Glim 4 mg., Week 24/EW|Change From Baseline in Total Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C), Low Density Lipoprotein-cholesterol (LDL-C), and Triglyceride (TG) at Week 24/EW, Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, HDL-C, LDL-C, TG) assessment. The lipid profile asesses the risk of heart disease. Change from Baseline in TC, HDL-C, LDL-C, and TG was calculated as the value at Week 24)/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW, Blood samples of participants were collected for BUN and electrolyte (sodium, potassium, chloride, calcium, and phosphorus) assessment. The electrolyte balance asseses the condition of the heart and the kidneys, and BUN assesses the condition of the kidneys. Change from Baseline in BUN, sodium, potassium, chloride, calcium, and phosphorus was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in the Ratio of TC/HDL-C and LDL-C/HDL-C at Week 24/EW, Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, HDL-C and LDL-C) assessment. The ratio of TC/HDL-C and LDL-C/HDL-C was calculated. Change from Baseline in the ratio of TC/HDL-C and LDL-C/HDL-C was calculated as the value at Week 24/EW minus the value at Baseline. For TC/HDL-C, the numerator is TC, and the denominator is HDL-C. For LDL-C/HDL-C, the numerator is LDL-C, and the denominator is HDL-C., Baseline (Week 0) and Week 24/EW|Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW, Blood samples of participants were collected for hs-CRP assessment. CRP is a marker of inflammation. High levels of CRP predict the risk of heart disease and diabetes. Change from Baseline in hs-CRP was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Percent Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW, Blood samples of participants were collected for hs-CRP assessment. CRP is a marker of inflammation. High levels of CRP predict the risk of heart disease and diabetes. Percent change from Baseline in hs-CRP was calculated as the value at Visit 8 (Wk 24)/ EW minus the value at Baseline divided by value at Wk 24/ EW multiplied by 100., Baseline (Week 0) and Week 24/EW|Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) at Week 24/EW, EQ-5D is used as a measure of health outcome and includes single-item measures (coded on a 3-point scale \[1, no problems; 2, some problems; 3, severe problems\]) of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The instrument includes a global rating of current health using a visual analog scale (VAS): 0 (worst imaginable) to 100 (best imaginable). Health states may be converted to a single summary index by applying a formula that attaches values to each of the levels in each dimension. The index scale is -0.111 to 1. A lower index indicates worse health., Baseline (Week 0) and Week 24/EW|Change From Baseline in Adjusted Diabetes Quality of Life (A-DQOL) Scores at Week 24/EW, In diabetic participants, QOL, anxiety, and depression were measured by the A-DQOL scale . There are 46 core items (10 additional items for adolescents) and 4 major dimensions: treatment satisfaction, treatment impact, worry about long-term complications, and worry about social/vocational issues. Participants respond to all items on a 5-point Likert scale: 1, no impact, no worries, or always satisfied; 5, always affected, always worried, or never satisfied. The total score is a sum of the individual scores of all 46 items (range of 46 to 230); a lower score indicates a better QOL., Baseline (Week 0) and Week 24/EW|Number of Participants With Hypoglycemic Events, Blood samples of participants were collected for the assessment of blood glucose levels. Hypoglycemia is a condition that occurs when the blood glucose is below 70 mg/dL or 4 mmol/L. All participants; participants with HbA1c \<7%, or who achieved a decrease of \>= 0.7% from Baseline at Week 24 (HbA1c responders); and participants who had a \>=1.7 mmol/L decrease from Baseline FPG or who achieved a FPG \<6.1 mmol/L at Week 24 (FPG responders) were evaluated., Week 24/EW|Number of Hypoglycemic Events, A hypoglycemic event is a condition that occurs when the blood glucose is below 70 mg/dL or 4 mmol/L. All participants, participants with HbA1c \<7%, or who achieved a decrease of \>= 0.7% from Baseline at Week 24 (HbA1c responders);" and participants who had a \>=1.7 mmol/L decrease from Baseline FPG or who achieved a FPG \<6.1 mmol/L at Week 24 (FPG responders) were evaluated., Week 24/EW|Number of Participants With a Bone Fracture, Participants with a break in the continuity (fracture) of the bone were evaluated., Week 24/EW|Change From Baseline in White Blood Cell (WBC) Count and Platelet Count at Week 24/EW, Blood samples of participants were collected for WBC count and platelet count assessment. Change from Baseline in WBC count and platelet count was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Red Blood Cell (RBC) Count at Week 24/EW, Blood samples of participants were collected for RBC count assessment. Change from Baseline in RBC count was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW, Blood samples of participants were collected for lymphocyte, monocyte, neutrophil, eosinophil, and basophil assessment. Change from Baseline in lymphocytes, monocytes, neutrophils, eosinophils, and basophils was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Hematocrit (HCT) at Week 24/EW, Blood samples of participants were collected for HCT assessment. Change from Baseline in HCT was calculated as the value at Week 24/EW minus the value at Baseline. HCT is measured as the percentage of the volume of whole blood that is made up of red blood cells., Baseline (Week 0) and Week 24/EW|Change From Baseline in Hemoglobin (HE), Mean Corpuscular Hemoglobin Concentration (MCHC), Total Protein (TP), and Albumin at Week 24/EW, Blood samples of participants were collected for HE, MCHC, and TP assessment. Change from Baseline in HE, MCHC, and TP was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Mean Corpuscular Volume (MCV) at Week 24/EW, Blood samples of participants were collected for MCV assessment. Change from Baseline in MCV was calculated as the value at Week 24/EW minus the value at Baseline. MCV is the average size of the red blood cells expressed in femtoliters. MCV is calculated by dividing the hematocrit (as percent) by the RBC count in millions per microliter of blood, then multiplying by 10. MCV is one of the three main RBC indices that are helpful in determining the cause of anemia., Baseline (Week 0) and Week 24/EW|Change From Baseline in Mean Corpuscular Hemoglobin (MCH) at Week 24/EW, Blood samples of participants were collected for MCH assessment. Change from Baseline in MCH was calculated as the value at Week 24/EW minus the value at Baseline. MCH is the average amount of hemoblobin inside a RBC expressed in picograms. MCH is calculated by dividing the hemoglobin concentration in grams per deciliter by the RBC count in millions per microliter, then multiplying by 10. MCH is one of the three main RBC indices which are helpful to determine the cause of anemia., Baseline (Week 0) and Week 24/EW|Change From Baseline in Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP), and Creatine Kinase (CK) at Week 24/EW, Blood samples of participants were collected for ALT, AST, GGT, LDH, ALP, and CK assessment. Change from Baseline in ALT, AST, GGT, LDH, ALP, and CK was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Total Bilirubin (TB), Direct Bilirubin (DB), Creatinine, and Uric Acid (UC) at Week 24/EW, Blood samples of participants were collected for TB, DB, creatinine, and UC assessment. Change from Baseline in TB, DB, creatinine, and UC was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Week 24/EW, The blood pressure of the participants was measured. Change from Baseline in SBP and DBP was calculated as the value at Weeks 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Heart Rate at Week 24/EW, The heart rate of the participants was measured. Change from Baseline in heart rate was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Weight at Week 24/EW, The weight of the participants was measured. Change from Baseline in weight was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Electrocardiogram (ECG) Assessment of Heart Rate at Week 24/EW, Electrocardiograms of the participants were taken for the evaluation of heart rate. Change from Baseline in heart rate was calculated as the value at Week 24/EW minus the value at Baseline., Baseline (Week 0) and Week 24/EW|Change From Baseline in Electrocardiogram (ECG) Data at Week 24/EW, PR, QT, QTc, RR, QRS, and QRS axis data were measured by ECG. The PR interval (int.) starts at the beginning of the atrial contraction and ends at the beginning of the ventricular contraction. QT (QT int.) and QTc (corrected QT int.) indicate how fast the ventricles are repolarized, becoming ready for a new cycle. The RR int. represents the duration of the ventricular cardiac cycle and is an indicator of ventricular rate. QRS (QRS duration) indicates how fast the ventricles depolarize. The QRS axis is an indicator of the electrical heart axis, which is an average of all heart depolarization., Baseline (Week 0) and Week 24/EW"","
"NCT01332149,""Baseline Mean Pain Score, The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10., Baseline|Change From Baseline in Mean Pain Score at Endpoint, The daily pain rating scale (DPRS) consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint pain score was obtained from the last 7 available DPRS scores of the daily pain diary while the participant was on study medication, up to and including the day after the last Week 8 (Day 57) dose., Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)"",""Change From Baseline in Weekly Mean Pain Score at Weeks 1 to 9, The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean pain score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9., Baseline and weekly from Weeks 1 to 9|Baseline Mean Sleep Interference Score, Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10., Baseline|Change From Baseline in Mean Sleep Interference Score at Endpoint, Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The mean endpoint score was obtained from the last 7 available scores of the daily diary while the participant was on study medication, up to and including the day after the last Week 9 (Day 63) dose., Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)|Change From Baseline in Weekly Mean Sleep Interference Score at Weeks 1 to 9, Pain-related sleep interference was assessed on an 11-point numerical rating scale ranging from 0 (did not interfere with sleep) to 10 (completely interfered \[unable to sleep due to pain\]). Participants were to describe how their pain had interfered with their sleep during the past 24 hours by choosing the appropriate number between 0 and 10. The weekly mean score was the sum of the daily scores divided by the number of diary entries during that week. The overall change is the average change from Weeks 1 to 9., Baseline and weekly from Weeks 1 to 9|Percentage of 30 Percent (%) Responders at Endpoint, The DPRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst possible pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10. A 30% responder was a participant who had 30% reduction or more in mean pain score at the end of the fixed dose phase (Day 63/Week 9) (Study Endpoint) compared to baseline., End of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)|Change From Baseline in Short Form McGill Pain Questionnaire (SF-MPQ) Score at Weeks 1, 5, and 9, SF-MPQ was assessed according to the participant's answer to the SF-MPQ questionnaire. The score for each composite scale (sensory, affective, and total) was derived by summing the reported intensity value for each item within a particular scale where None=0, Mild=1, Moderate=2, and Severe=3. The sensory score was the sum of the scores of the first 11 pain descriptors (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching, heavy, tender, and splitting) and could range from 0-33. The affective score was the sum of the scores of the last 4 pain descriptors (tiring-exhausting, sickening, fearful, and punishing-cruel) and could range from 0-12. The total score was the sum of the scores of all 15 pain descriptors and could range from 0 to 45. Higher scores indicated greater pain., Baseline"; Weeks 1, 5, and 9|Baseline Pain Visual Analogue Scale (VAS) and Present Pain Intensity (PPI) Scale, The VAS was part of the Short Form McGill Pain Questionnaire (SF-MPQ) scale and reflected the overall pain intensity score, The pain VAS was a horizontal line; 100 millimeters (mm) in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain). The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating)., Baseline|Change From Baseline in Pain VAS From the SF-MPQ at Endpoint, The VAS was part of the SF-MPQ scale and reflected the overall pain intensity score. The pain VAS was a horizontal line; 100 mm in length, was self-administered by the participant in order to rate pain from 0 (no pain) to 100 (worst possible pain)., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in PPI Scale From the SF-MPQ at Endpoint, The PPI was part of the SF-MPQ scale and measured the participant's present pain intensity on a 6-point scale ranging from 0 (no pain) to 5 (excruciating)., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Baseline Medical Outcomes Study (MOS)-Sleep Scale Scores, The MOS-Sleep Scale was a participant-rated instrument which assesses sleep quantity and quality with 12 items (7 subscale scores: sleep disturbance, snoring, awakening short of breath/with headache, sleep adequacy, somnolence, sleep quantity, optimal sleep; and a 9-item overall sleep problems index). Subscale scores total range: 0-100 (except sleep quantity \[range 0-24 hours\], optimal sleep \[yes:1, no:0\]). Higher scores=poorer sleep outcomes (except sleep quantity, adequacy, and optimal sleep)., Baseline|Change From Baseline in MOS-Sleep Scale, Sleep Disturbance Score at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. For sleep disturbance, the subscale score also ranged from 0 to 100, with higher scores representing greater sleep disturbance., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in MOS-Sleep Scale, Snoring Score at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The snoring subscale score also ranged from 0 to 100, with lower scores indicating less snoring., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in MOS-Sleep Scale, Awaken Short of Breath Score at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The awaken short of breath subscale also ranged from 0 to 100, with lower scores indicating less difficulty in breathing., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in MOS-Sleep Scale, Quantity of Sleep Score at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS Sleep Quantity sub-scale scores ranged from 0 to 24 (number of hours slept)., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Percentage of Participants Who Had Optimal Sleep at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The MOS optimal sleep subscale was a binary outcome derived from the sleep quantity responses: the response was YES if sleep quantity was 7 or 8 hours per night., Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in MOS-Sleep Scale, Sleep Adequacy Score at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep adequacy subscale also ranged from 0 to 100, with higher scores indicating greater sleep adequacy., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in MOS-Sleep Scale, Somnolence Score at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The somnolence subscale score also ranged from 0 to 100, with lower scores indicating less somnolence., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in MOS-Sleep Scale, Sleep Problems Index Score at Endpoint, The MOS-Sleep Scale was a participant-rated questionnaire consisting of 12 items that assessed key constructs of sleep. Instrument scoring yielded 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. The total score ranged from 0 to 100. The sleep problems index subscale score also ranged from 0 to 100, with lower scores indicating fewer sleep problems., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Clinical Global Impression of Change (CGIC) at Endpoint, The CGIC was a clinician-rated global measure that provided a clinically relevant and easy to interpret account of a clinician's perception of the clinical importance of the participant's improvement or worsening during their involvement in a clinical study. Clinicians rated the participant's overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse)., Day 63 (Week 9)/Early Termination (Study Endpoint)|Patient Global Impression of Change (PGIC) Score at Endpoint, The PGIC was a participant-rated global measure that provided a clinically relevant and easy to interpret account of a participant's perception of the clinical importance of their own improvement or worsening during their involvement in a clinical study. Participants rated their overall improvement on a 7-point scale where scores ranged from 1 (very much improved) to 7 (very much worse)., Day 63 (Week 9)/Early Termination (Study Endpoint)|Baseline Hospital Anxiety and Depression Scale (HADS) Scores, The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe., Baseline|Change From Baseline in HADS Anxiety Total Score at Endpoint, The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items; participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)|Change From Baseline in HADS Depression Total Score at Endpoint, The HADS was a self-administered questionnaire that consisted of 2 subscales, 1 measuring anxiety (HADS-A Scale) and the other measuring depression (HADS-D Scale). Each subscale was comprised of 7 items;" participants assessed how each item applied to them on a scale of 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Subscores from HADS-A (Anxiety) and HADS-D (Depression) were not to be combined. The interpretation of each HADS subscales was as follows: 0-7 normal, 8-10 mild, 11-14 moderate and 15-21 severe., Baseline and Day 63 (Week 9)/Early Termination (Study Endpoint)"",";;;;;
"NCT00441363,""Change in Baseline to End of Study in HbA1c, Too few subjects were enrolled to assess outcome to pre-specified statistical power., up to 24 weeks"",""Fasting Plasma Glucose and Lipids, up to 24 weeks|Number of Serious Adverse Events Experienced by the Subjects, up to 24 weeks"",";;;;;;;;;;;;
"NCT00950963,""Number of Patients With a Low Density Lipid (LDL) Value Less Than 100 mg/dL, Number of patients with and without cardiovascular disease (CVD) with LDL value less than 100 mg/dL at the end of the study, 18 months"",""Number of CVD Patients With LDL Less Than 70 mg/dL., 18 months|Number of Patients With BP Less Than 130/80 mm Hg, Number of patients meeting blood pressure goals as defined by the American Diabetes Association guidelines., 18 months|Number of Patients With Hgb A1c Less Than 7 Percent at the End of the Study, Number of patients with Hgb A1c as recommended by the American Diabetes Association guidelines., 18 months"",""Number of Total Emergency Department (ED) Visits and Hospital Admissions During the Follow up Period., Evaluate the effect of the intervention on healthcare utilization as defined by ED visits and hospitalizations, 18 months""";;;;;;;;;;;;
"NCT00655863,""Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16., The change in postprandial (after eating a meal) incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC (0-8h)) postdose at week 16 relative to baseline., Baseline and Week 16."",""Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 4., The change in postprandial incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC(0-8h)) postdose at week 4 relative to baseline., Baseline and Week 4.|Change From Baseline in Postprandial Incremental Area Under the Curve Changes for Lipid Parameters., The change in postprandial incremental area under the plasma concentration-time curve for very-low-density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL2 cholesterol, VLDL2 triglycerides, chylomicron cholesterol, chylomicron triglycerides, intermediate-density lipoprotein (IDL) cholesterol, and IDL triglycerides from 0 to 8 hours postdose at week 4 and week 16 relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in Postprandial Incremental Area Under the Curve for Lipoprotein Parameters., Postprandial incremental area under the curve changes for very-low-density lipoprotein (VLDL) Apo B-48, VLDL Apo B 100, VLDL2 Apo B-48, VLDL2 Apo B 100, chylomicron Apo B-48, chylomicron Apo B 100, and intermediate density lipoprotein (IDL) Apo B-48, IDL Apo B 100, and triglyceride-rich remnant (TRR) lipoproteins from 0 to 8 hours postdose at week 4 and week 16 relative to baseline., Baseline, Week 4 and Week 16.|Postprandial Changes Over Time From Baseline for Glucagon-like Peptide-1 (GLP-1), Postprandial changes over time at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Postprandial Changes Over Time From Baseline for Glucose, Postprandial changes over time at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Postprandial Changes Over Time From Baseline for Insulin, Postprandial changes over time at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Postprandial Changes Over Time From Baseline for Glucagon, Postprandial changes over time at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in Glycosylated Hemoglobin, The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline., Baseline, Week 8 and Week 16.|Change From Baseline in Fasting Plasma Glucose, The change in fasting plasma glucose collected at each week indicated relative to baseline., Baseline, Week 4, Week 8 and Week 16.|Change From Baseline in Postprandial C-Peptide, The change in postprandial C-peptide collected at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in Postprandial Proinsulin, The change in postprandial proinsulin collected at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in High-sensitive C-reactive Protein (Hs-CRP), The change in hs-CRP collected at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in Adiponectin, The change in adiponectin collected at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in Anti-Vascular Cell Adhesion Molecule (VCAM), The change in VCAM collected at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in Anti-Intercellular Adhesion Molecule (ICAM), The change in ICAM collected at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in e-Selectin, The change in e-Selectin collected at each week indicated relative to baseline., Baseline, Week 4 and Week 16.|Change From Baseline in Endothelial Function Through Pulse Wave Tonometry, Pulse wave tonometry performed before the meal and 2 hours postmeal using one recording consisting of 15 to 20 sequentially recorded radial artery waveforms collected at each assessment., Baseline and Week 16."",";;;;;;;;;;;;
"NCT01467063,""Insulin Sensitivity, Insulin sensitivity as measured by hyperinsulinemic-euglycemic clamp. Insulin sensitivity was calculated by dividing the average glucose infusion rate (mL glucose infusion/kg body weight/min) by the average insulin concentration (uU/mL)., During the Hyperinsulinemic-Euglycemic Clamp, an average of 3 hours"",""Glucagon-like Peptide 1 (GLP-1), Post-Infusion"",";;;;;;;;;;;;
"NCT02492763,""Change From Baseline in Hemoglobin A1C (A1C) at Week 12, A1C is the percentage of hemoglobin that has glucose bound to it and is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is reported as a percentage (%). This change from baseline reflects the Week 12 A1C minus the Week 0 A1C., Baseline and Week 12|Number of Participants With an Adverse Event (AE), An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study., Up to Week 14|Number of Participants Who Discontinued Study Treatment Due to an AE, An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study., Up to Week 12|Number of Participants With an AE of Symptomatic Hypoglycemia, An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Hypoglycemia episodes are those with glucose values ≤70 mg/dL (3.9 mmol/L). Symptomatic hypoglycemia episodes were episodes with clinical symptoms reported by the investigator as hypoglycemia and classified as adverse events., Up to Week 14|Change From Baseline in Heart Rate at Week 12, This change from baseline reflects the Week 12 heart rate minus the Week 0 heart rate., Baseline and Week 12"",""Change From Baseline in Body Weight at Week 12, This change from baseline reflects the Week 12 body weight minus the Week 0 body weight., Baseline and Week 12|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12, This change from baseline reflects the Week 12 FPG minus the Week 0 FPG., Baseline and Week 12|Change From Baseline in Fasting Low Density Lipoprotein (LDL) Cholesterol at Week 12, This change from baseline reflects the Week 12 fasting LDL cholesterol minus the Week 0 fasting LDL cholesterol., Baseline and Week 12|Change From Baseline in Fasting High Density Lipoprotein (HDL) Cholesterol at Week 12, This change from baseline reflects the Week 12 fasting HDL cholesterol minus the Week 0 fasting HDL cholesterol., Baseline and Week 12|Change From Baseline in Fasting Triglycerides at Week 12, This change from baseline reflects the Week 12 fasting triglycerides minus the Week 0 fasting triglycerides., Baseline and Week 12|Change From Baseline in Systolic Blood Pressure (SBP) at Week 12, This change from baseline reflects the Week 12 SBP minus the Week 0 SBP., Baseline and Week 12|Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12, This change from baseline reflects the Week 12 DBP minus the Week 0 DBP., Baseline and Week 12"",";;;;;;;;;;;;
"NCT01255163,""Number of Participants With Incidence of Nausea, Tolerability of exenatide (nausea is the most common expected adverse event of exenatide), 18 months"",""Mini Mental State Examination (MMSE), Scale range: 0 - 30 points (higher is better), 18 months|Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog70), Alzheimer's dementia scale cognitive sub-scale range: 0 - 70 points (higher is worse), 18 months|Clinical Dementia Rating (CDR) Global Score, Clinical Dementia Rating global score range: 0 (no dementia)"; 0.5 (Mild Cognitive Impairment); 1 (mild dementia); 2 (moderate dementia);" 3 (severe dementia). Higher is worse., 18 months|Clinical Dementia Rating (CDR) Sum of Boxes, Sum of the Clinical Dementia Rating """"boxes"""" (memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care). Each box is rated as 0, 0.5, 1, 2 or 3. Range for the sum of boxes is 0 - 18. Higher scores reflect a greater severity of dementia., 18 months|Cerebrospinal Fluid (CSF) Total Tau, Total Tau measured in CSF using Luminex xMAP technology and INNO-BIA Alz Bio3 kits (Research Use Only) provided by Fujirebio, 18 months|Cerebrospinal Fluid phospho181-tau (CSF p181-tau), p-181-Tau measured in CSF using Luminex xMAP technology and INNO-BIA Alz Bio3 kits (Research Use Only) provided by Fujirebio, 18 months|Cerebrospinal Fluid Amyloid-beta 42 (CSF Abeta42), Abeta42 peptide measured in CSF using Luminex xMAP technology and INNO-BIA Alz Bio3 kits (Research Use Only) provided by Fujirebio, 18 months|Body Mass Index (BMI), Body Mass Index defined as a person's weight in kilograms (kg) divided by his or her height in meters squared., 18 months"",";;;;;;;;
"NCT00338949,""Change in Insulin Sensitivity Index From Baseline to Week 26 ((1/mU/L) x 1/Min), As measured by frequently sampled intravenous glucose tolerance testing (units: 1/mU/L) x 1/Min), Measured at Baseline and Week 26|Change in Visceral Fat Mass From Baseline to Week 26, CT measured change in visceral fat mass from baseline to week 26 (mm\^3), Baseline and Week 26"",,";;;;;;;;;;;;
"NCT01778049,""Change From Baseline of HbA1c After 24 Weeks of Treatment., Change from baseline in Glycated haemoglobin (HbA1c) \[%\] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term """"baseline"""" was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as """"pre-treatment"""". Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference.";;;;;;;;;;;;